LexDanaLexDanabeta
Inventor

Mark G. Erlander

Inventor
Encinitas, CA, US

Overview

51→
Patents
1995–2021
Patent span
Chemistry
Primary field (CPC C)

Patents· 51 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

C12Nprimary
C12NMicroorganisms or enzymes20%
C12QMeasuring or testing processes involving enzymes, nucleic acids or microorganisms16%
A61KPreparations for medical, dental or toiletry purposes14%
C07KPeptides14%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations11%
G01NInvestigating or analysing materials by determining their chemical or physical properties9%
C12YEnzymes7%
G16BBioinformatics, i.e. information and communication technology [ict] specially adapted for genetic or protein-related data processing in computational molecular biology5%
Y10STechnical subjects covered by former uspc cross-reference art collections [xracs] and digests3%
G06FElectric digital data processing1%
PatentTitleYear
11,078,538Post-treatment breast cancer prognosis202111,021,754Tumor grading and cancer prognosis202110,538,816Identification of tumors202010,329,624Grading of breast cancer201910,253,369Predicting likelihood of response to combination therapy201910,036,060Nucleic acid amplification20189,856,533'Predicting breast cancer treatment outcome'20189,725,755'Synthesis and enrichment of nucleic acid sequences'20179,670,553'Determining tumor origin'20179,447,470'Tumor grading and cancer prognosis'20168,926,966'Cloned glutamic acid decarboxylase'20158,895,269'Gene expression profiling from FFPE samples'20148,435,739'Gene expression profiling from FFPE samples'20138,012,688'Gene expression profiling from FFPE samples'20117,930,105'Grading of breast cancer'20117,879,555'Gene expression profiling from FFPE samples'20117,723,039'Gene expression profiling from FFPE samples'20107,504,214'Predicting outcome with tamoxifen in breast cancer'20097,364,846'Gene expression profiling from FFPE samples'20087,329,511'Nucleic acid encoding GAD65'20087,186,803'Human vanilloid receptor VR3 protein'20077,179,604'Methods of use of DNA encoding a human histamine receptor of the H3 subtype'20077,109,296'Human 5-HT3-C protein'20067,094,877'Human vanilloid receptor VR3 protein'20067,049,401'Human histamine receptor of the H3 subtype'20066,855,560'Method of identifying compounds that modulate human histamine H3 receptor'20056,794,141'Nucleic acid amplification'20046,682,906'Cloned glutamic acid decarboxylase'20046,596,484'Method for simultaneous sequence-specific identification and display of mRNA\'s'20036,548,270'DNA encoding human acid-sensing ion channel BNaC4 (ASIC4)'20036,455,278'DNA encoding human vanilloid receptor VR3'20026,455,267'Methods and kits useful for determining the status of and detecting pancreatic B-cell associated autoimmune diseases'20026,437,100'DNA encoding a human histamine receptor of the H3 subtype'20026,413,743'DNA encoding a human histamine receptor of the H3 subtype'20026,365,370'DNA encoding a human subunit 5-HT3-C of the 5-HT3 serotonin receptor'20026,358,706'DNA encoding human alpha1G-C T-Type calcium channel'20026,309,834'Method for simultaneous identification of differentially expressed mRNAs and measurement of relative concentrations'20016,277,586'Cloned glutamic acid decarboxylase'20016,136,559'DNA encoding as human histamine receptor of the H3 subtype'20006,110,680'Method for simultaneous identification of differentially expressed mRNAs and measurement of relative concentrations'20006,107,476'Nucleic acid molecule encoding a protein growth factor for inhibiting prostate cancer cell growth'20006,030,784'Method for simultaneous identification of differentially expressed mRNAS and measurement of relative concentrations'20006,011,139'Hybridomas and monoclonal antibodies that specifically bind to glutamic acid decarboxylase peptides'20005,998,366'Method for ameliorating glutamic acid decarboxylase associated autoimmune disorders'19995,968,817'DNA encoding serotonin receptors'19995,846,740'Methods and kits useful for detecting autoantibody to glutamic acid decarboxylase'19985,807,680'Method for simulataneous identification of differentially expresed mRNAS and measurement of relative concentrations'19985,705,626'Cloned glutamic acid decarboxylase nucleic acids'19985,674,978'Peptides derived from glutamic acid decarboxylase'19975,475,086'Cloned glutamic acid decarboxylase peptides'19955,459,037'Method for simultaneous identification of differentially expressed mRNAs and measurement of relative concentrations'1995

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

1995–2015Patents assigned to UNIV CALIFORNIA (11)· patent assignee history
1995–2003Patents assigned to SCRIPPS RESEARCH INST (7)· patent assignee history
1995–2011Based in Encinitas, CA, US· patent location history
1995–2015Based in Tarzana, CA, US· patent location history
2000–2007Patents assigned to ORTHO MCNEIL PHARM INC (11)· patent assignee history
2002–2017Based in San Diego, CA, US· patent location history
2009–2021Patents assigned to BIOTHERANOSTICS INC (10)· patent assignee history
2011–2021Based in Carlsbad, CA, US· patent location history
2013–2018Patents assigned to ERLANDER MARK G (5)· patent assignee history
2018–2020Based in Redwood City, CA, US· patent location history

Inventor activity

Assignee and location history derived from the patent record.

Assignees
AssigneePatentsSpan
ORTHO MCNEIL PHARM INC112000–2007
UNIV CALIFORNIA111995–2015
BIOTHERANOSTICS INC102009–2021
SCRIPPS RESEARCH INST71995–2003
ERLANDER MARK Gself52013–2018
Locations
LocationPatentsSpan
Encinitas, California, US251995–2011
Tarzana, California, US111995–2015
Carlsbad, California, US82011–2021
San Diego, California, US32002–2017
Redwood City, California, US22018–2020